Results 41 to 50 of about 164,783 (254)

Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund, Johan Reutfors, Thomas Frisell, Fredrik Piehl   +3 more
wiley   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of
Pannathat Soontrapa, Iago Pinal‐Fernandez, Pritikanta Paul, Michael P. Skolka, Margherita Milone, Min Shi, Mithun V. Shah, Maria Casal‐Dominguez, Katherine Pak, Andrew L. Mammen, Teerin Liewluck   +10 more
wiley   +1 more source

USE OF INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION IN CHILDREN AND ADOLESCENTS WITH MULTIPLE SCLEROSIS: EFFICACY, SAFETY AND ADHERENCE TO THERAPY

Педиатрическая фармакология, 2009
Immunomodulatory drugs reduce relapse rate and disease progression in relapsing-remitting multiple sclerosis but extensive data are not available on the effectiveness and tolerability of these drugs in childhood or adolescence.
O.V. Bykova, T.V. Sidorenko, A.N. Platonova, N.V. Gol’tsova, L.M. Kuzenkova, A.N. Boiko   +5 more
doaj   +2 more sources

Thrombotic microangiopathy associated with use of interferon-beta

International Journal of Nephrology and Renovascular Disease, 2012
Teresa Olea,1 Raquel Díaz-Mancebo,1 Maria-Luz Picazo,2 Jorge Martínez-Ara,1 Angel Robles,3 Rafael Selgas,11Departments of Nephrology, 2Pathology, 3Internal Medicine, Hospital Universitario La Paz, Madrid, SpainAbstract: Interferon ...
Robles A, Martinez-Ara J, Picazo ML, Diaz-Mancebo R, Olea T, Selgas R   +5 more
doaj  

Interferon beta 1-a na esclerose múltipla: experiência de um ano em 62 pacientes [PDF]

Arquivos de Neuro-Psiquiatria, 2000
Relatamos os resultados de estudo com o interferon beta 1-a em 62 pacientes ambulatoriais com a forma remitente-recorrente da esclerose múltipla durante um ano. Os critérios de inclusão para este tratamento foram de escore do EDSS entre 0 e 5,5 e de pelo
CHARLES P. TILBERY, EDUARDO FELIPE, MARCOS A. MOREIRA, MARIA F. MENDES, ANDREA S. FRANÇA   +4 more
doaj   +1 more source

A Prospective Study of Individuals at Risk of Multiple Sclerosis Informs the Design of Primary Prevention Studies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective In multiple sclerosis, the optimal time for deploying a therapeutic intervention is before the central nervous system is damaged; given the success of trials treating the earliest stage of MS, the radiologically isolated syndrome, developing primary prevention strategies is an important next challenge.
Amy W. Laitinen, Ceren Tozlu, Tina Roostaei, Fatoumata Diallo, Kaho Onomichi, Jiyeon Son, Zongqi Xia, Philip L. De Jager   +7 more
wiley   +1 more source

Paramagnetic Rim Lesions Are Associated With Trans‐Synaptic Degeneration of the Visual Pathway in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Retrograde trans‐synaptic degeneration (rTSD) from posterior visual pathway lesions in multiple sclerosis (MS) is characterized by hemi‐macular ganglion cell‐inner plexiform layer (GCIPL) thinning and contralateral visual field loss.
Abdul Jaber Tayem, Angel Liu, Sargis Manukyan, Mustafa Subhi, Elaina Luskin, Bryan Quah, Sreekanth Madhusoodhanan Nair, Arzu C. Has Silemek, Gabriela Zabala, Yujie Cui, Laura Locke, Paula Barreras, Marwa Kaisey, Vinicius Calsavara, Daniel S. Reich, Nancy L. Sicotte, Pascal Sati, Omar Al‐Louzi   +17 more
wiley   +1 more source

Interferon-beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription [PDF]

Acta Medica Iranica, 2012
None of the approved immunomodulatory drugs in adults Multiple Sclerosis (MS) patients have been officially approved for the pediatric patients and are currently used off-label in this population.
Keivan Basiri, Masood Etemadifar, Fatemeh Derakhshan, Fereshteh Ashtari, Vahid Shaygannejad, Zahra Fatehi, Amir Hadi Maghzi, Farzad Fatehi   +7 more
doaj   +1 more source

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2010
Background: Mycophenolate mofetil (MMF, CellCept ® ) has been utilized as an antirejection agent in transplant recipients and in patients with myriad autoimmune disorders including multiple sclerosis (MS).
Elliot M. Frohman, Gary Cutter, Gina Remington, Hongjiang Gao, Howard Rossman, Bianca Weinstock-Guttman, Jacqueline E. Durfee, Amy Conger, Ellen Carl, Katherine Treadaway, Eric Lindzen, Amber Salter, Teresa C. Frohman, Anjali Shah, Angela Bates, Jennifer L. Cox, Michael G. Dwyer, Olaf Stuve, Benjamin M. Greenberg, Michael K. Racke, Robert Zivadinov   +20 more
doaj   +1 more source